Trial Parameters
Brief Summary
The primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESKD), according to dose (full-dose vs reduced-dose), ethnicity (Chinese vs other) and kidney function (eGFR above and below 60 mL/min/1.73m2).
Eligibility Criteria
Inclusion Criteria: 1\) Only participants who were randomised into the TESTING trial Exclusion Criteria 1. Participants who have reached kidney failure requiring maintenance dialysis or kidney transplantation during the TESTING trial 2. Participants who died during the TESTING trial 3. Participants who had withdrawn their consent during the TESTING trial 4. Participants who are unable to provide consent for some other reason